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Background. Chronic pain is associatedwith increasedmorbidity andmortality, predominated by cardiovascular disease and cancer.
Investigating related risk factor measures may elucidate the biological burden of chronic pain. Objectives. We hypothesized that
chronic pain severity would be positively associated with the risk factor composite.Methods. Data from 12,982 participants in the
6th Tromsø study were analyzed. Questionnaires included demographics, health behaviors, medical comorbidities, and chronic
pain symptoms. The risk factor composite was comprised of body mass index, fibrinogen, C-reactive protein, and triglycerides.
Chronic pain severity was characterized by frequency, intensity, time/duration, and total number of pain sites. Results. Individuals
with chronic pain had a greater risk factor composite than individuals without chronic pain controlling for covariates and after
excluding inflammation-related health conditions (𝑝 < 0.001). A significant “dose-response” relationship was demonstrated with
pain severity (𝑝 < 0.001). In individuals with chronic pain, the risk factor composite varied by health behavior, exercise, lower
levels and smoking, and higher levels. Discussion. The risk factor composite was higher in individuals with chronic pain, greater
with increasing pain severity, and influenced by health behaviors. Conclusions. Identification of a biological composite sensitive to
pain severity and adaptive/maladaptive behaviors would have significant clinical and research utility.
1. Introduction
Living with pain is linked with poor health and increased
morbidity and mortality [1–5]. Individuals reporting “pain
lasting at least one day during the past month” showed
an increased incidence of and poorer survival rate from
cancer [1] and an increased all-cause mortality over an eight-
year period compared to those without pain [6]. Chronic
widespread pain was associated with higher mortality rates
over a 12-year period [3]. Further, Torrance and colleagues
(2010) reported that severe chronic pain was related to
increased all-cause mortality and to circulatory system dis-
ease deaths [5].
One method to initiate the investigation of the biological
burden related to chronic pain is to explore biological mea-
sures associatedwith disease states linkedwith increased inci-
dence of morbidity and mortality in individuals with chronic
pain. For example, the leading causes of increased mortality
reported in musculoskeletal and widespread pain conditions
include cancer, cardiovascular disease, and other circulatory
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conditions [2, 3, 5, 7]. VanDenKerkhof and colleagues found
that lifestyle factors (body mass index and smoking) and
diet (in women) may contribute to the chronic widespread
pain and cancer and cardiovascular disease relationship [8].
Additionally, cardiovascular risk factors related to metabolic
syndrome were also associated with chronic pain [9]. Thus,
investigating biological measures that are known risk factors
for cardiovascular disease and cancer and that are associated
with stress regulatorymechanisms, such as inflammatory and
metabolicmeasures,may help elucidate the biological burden
of chronic pain [10–12].
Frequently, research efforts have pursued the relationship
of a specific disease condition by focusing on an isolated bio-
logical factor. However, biological measures do not work in
isolation but rather interact in a complex array of systems [13,
14]. Additionally, the importance of considering a composite
of measures reflecting system functioning has been well sup-
ported [15]. C-reactive protein (CRP), fibrinogen, body mass
index (BMI), and triglycerides have been associated with the
risk and/or progression of cancer and cardiovascular disease
[16–18]. Importantly, in a large population based study [19],
ten measures reflecting multiple biological systems were
assessed and three measures were significantly associated
with experiences of pain: BMI, serum triglycerides, and CRP.
As previously noted, BMI was also associated with chronic
wide spread pain in another large population-based study [8].
Additionally, fibrinogen, an inflammatory biomarker, was
higher in individuals with versus without pain and fibrinogen
levels predicted pain at 12 months [20].
The purpose of this study was to investigate if chronic
pain is positively associated with a risk factor composite
comprised of known inflammatory and metabolic measures
linked with cancer and cardiovascular disease. We hypoth-
esized that (1) individuals with chronic pain would demon-
strate a higher risk factor composite compared to those indi-
viduals without chronic pain and that (2) a “dose-response”
relationship would be demonstrated between chronic pain
severity and the risk factor composite.
2. Methods
2.1. Sample. The Tromsø Study is a population-based study
with participants recruited from the municipality of Tromsø
in Northern Norway. The study thus far consists of six health
surveys, carried out every six or seven years since 1974. All
the surveys include questionnaire data, sampling of biological
specimens, and clinical measurements. The different surveys
are referred to as Tromsø 1–Tromsø 6 [21]. The current
investigation is a cross-sectional design based data from
the Tromsø 6 time point (collected from October 2007–
December 2008). The main purpose of Tromsø 6 was to
collect initial and repeated measurements of exposure data
from new and previous participants of the Tromsø Study.The
sample was recruited as follows: a 10% random sample of
individuals aged 30 to 39 (𝑛 = 1,056), all residents aged 40
to 42 and 60 to 87 (𝑛 = 12,578), a 40% random sample of
inhabitants aged 43 to 59 (𝑛 = 5,787), and all subjects who
had attended the second visit of Tromsø 4 but not already
included in the three groups above (𝑛 = 341). Of the invited
19,762 individuals, 65.7% participated in the Tromsø 6 survey
(𝑛 = 12,981), 53.4% were women, and ages ranged from 30–87
[22].
2.2. Ethics. Tromsø 6 was approved by the Data Inspectorate
of Norway and the present study was approved by the
Regional Committee of Medical and Health Research Ethics,
Northern Norway. The study complies with the Declaration
of Helsinki, International Ethical Guidelines for Biomedical
Research Involving Human Subjects, and the International
Guidelines for Ethical Review of Epidemiological Stud-
ies. Participation was voluntary. Each subject gave written
informed consent prior to participation in Tromsø 6 and for
the subsequent scientific use of the data.
2.3. Questionnaires. All participants completed two ques-
tionnaires, Q1 and Q2. Q1, four pages in length, was dis-
tributed together with an invitation letter and completed
before attending a medical examination. It covered topics
such as demographics, education level, various health issues,
symptoms, and diseases. Q2, 28 pages in length, coveredmore
detailed information on topics already covered in the Q1, as
well as some additional topics such as social network and life
contentment. Q2 was completed either during the first visit
or later at home and returned by mail. Those who answered
in response to Q1 that they have had persistent or recurring
pain with duration of three months or more were asked to fill
in a more detailed pain questionnaire, as part of Q2. A list of
the questionnaire items is available on the study homepage
(http://tromsoundersokelsen.uit.no/tromso/).
2.4. Demographic Information. Participant age and sex were
obtained from the Norwegian Central Population Registry.
Information about education level was obtained from Q1.
Analytically, age was treated as a categorical variable in
the analysis of variance and as a continuous variable in
the regression analysis. See Table 1 for age and education
categorical definitions.
2.5. Health Behaviors and Mental Health. Data on smoking,
alcohol consumption, and exercise were also obtained from
the Q1. Health behavior categories implemented in analyses
are listed inTable 1. Symptoms of anxiety and depressionwere
assessed with the Hopkins Symptom Checklist- (HSCL-) 10.
Participants scoring ≥1.85 were classified as having anxiety
and depression [23].
2.6. Chronic Pain. Participants were classified as having
chronic pain if they (a) answered “yes” to the question
“Do you have persistent or recurring pain that has lasted
three months or longer?” (b) stated that the pain occurred
once a month or more frequently, and (c) rated average pain
intensity as greater than zero on a 0–10-item numeric rating
scale (NRS) with the anchors “no pain” and “themost intense
pain imaginable.” Remaining participants were classified as
not having chronic pain.
2.7. Chronic Pain Severity. Chronic pain severity was mea-
sured in the group of individuals who endorsed having
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30–44 years 22.9 21.2 22.1
45–59 years 27.6 28.7 28.1
60–69 years 30.4 33.0 31.6
70–87 years 19.1 17.1 18.2
Higher education%
No 63.2 57.3 60.5
Yes 36.8 42.7 39.5
Chronic pain%
No 59.4 71.3 65.0
Yes 40.6 28.7 35.0
Smoking%
Never 40.4 33.8 37.3
Previously 38.2 46.9 42.3
Currently 21.4 19.3 20.4
Alcohol consumption%
Never 14.7 7.8 11.5
<4 units per month 24.4 15.8 20.4
4–16 units per month 39.4 43.2 41.2
>16 units per month 21.5 33.2 27.0
Exercise frequency
<Once per week 18.5 26.7 22.3
Once per week 18.5 21.4 19.9
2-3 times per week 40.7 36.3 38.7
>3 times per week 22.4 15.6 19.2
Note: higher education is defined as education >median for the age group.
chronic pain and completed a detailed pain questionnaire, as
part of the Q2 which included the following questions; the
response categories are listed in Table 2. The four domains
were selected based on their relevance to chronic pain
and their role in contributing to physiological change and
biological system dysregulation [2, 5, 24–29]:
(i) Frequency: How often do you have this pain? (every
day, ≥once a week, and ≥once a month).
(ii) Intensity: How strong would you say that the pain
usually is? 10-item numeric rating scale:
0 = no pain and 10 = worst imaginable pain.
(iii) Time (duration): How long have you had this pain?
(years or months).
(iv) Total pain sites: Where does it hurt? (head/face,
jaw/temporomandibular joint, neck, back, shoulder,
arm/elbow, hand, hip, thigh/knee/leg, ankle/foot,
chest/breast, stomach, genitalia/reproductive organs,
skin, or other locations).
A 50% frequency split was performed for each dimen-
sion, dichotomizing the variable to a 0 or 1 score. Chronic
pain severity, based on the four frequently captured pain
dimensions, frequency, intensity, time (duration), and total
number of pain sites (FITT), ranged from 1 to 5 designated
by a cumulative score resulting from a combined total of
the dichotomized values from the four pain dimensions [0
dimensions = a value of 1; one dimension = 2; two dimensions
= 3; three dimensions = 4; and four dimensions = 5]. Pain
dimensions are presented in Table 2.
2.8. Anthropometric and Biological Measures. Height and
weight were measured on an automatic electronic scale
[Jenix, DS 102 stadiometer (Dong Sahn Jenix, Seoul, Korea)].
Participants wore light clothing and no footwear. Body mass
index (BMI) was calculated as weight in kilograms divided by
the square of the height in meters (kg/m2).
The biological specimen collection and processing for
Tromsø 6 are described in detail [22]. Nonfasting blood
samples were collected twice, 50mL at the first visit and
20mL at the second visit. The participants were allowed to
drink water and black coffee during their visits. Venipunc-
ture was performed with subjects in a sitting position. A
light tourniquet was used and released prior to the blood
draw. After 30 minutes at room temperature, the coagulated
samples were centrifuged at 2000 g for 10 minutes, and the
sera were transferred within 1 hour to plastic tubes and kept
between 1∘C and 10∘C. The blood samples were delivered
twice daily to the Department of Laboratory Medicine,
University Hospital Northern Norway, Tromsø, which is an
accredited laboratory (ISO-standard 17025).
Fibrinogen was analyzed by a clotting assay with reagents
from IL (Instrumentation Laboratory, Milano, Italy) on
an ACL 3000 coagulation analyzer (Block Scientific Inc.,
Bohemia, New York). Serum triglycerides were analyzed
within 10 hours by an enzymatic colorimetric method. CRP
was analyzed by a highly sensitive CRP method (particle-
enhanced immunoturbidimetric assay). Analyses were per-
formed on a Modal PPE autoanalyzer with reagents from
Roche Diagnostics Norway AS.
2.9. Risk Factor Composite. The selection of the four mea-
sures was based on prior findings [19, 20] and available
biomarkers in the study: BMI, fibrinogen, CRP, and triglyc-
erides. A combined biomarker composite was constructed,
because (1) biological measures do not work in isolation but
rather in conjunction with a complex array of measures
[13, 29] and (2) a multisystem composite measure provides
a stronger predictor over individualized or single system
measures [15]. Due to skewed statistics, fibrinogen, CRP,
and triglycerides were natural log transformed and then
standardized to 𝑧 scores, and normalization of the data was
confirmed by review of histograms and summary statistics.
BMI was standardized without transformation. The four
𝑧 scores were then averaged to create a composite. Since
minor deviations from normality in the component variables
can produce deviation from normality in the risk factor
composite, the final composite was 𝑧-transformed to ensure
a mean of zero and SD of 1. A 𝑧 score composite is an
accepted formulation for biological measures allowing for
the standardization of all measures regardless of different
scales into the development of a continuous variable that is
comparable across all participants in the study, particularly
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Table 2: Pain dimensions: frequency, intensity, time, total pain sites, and chronic pain severity (FITT).
Pain dimensions Category Women Men Both
Frequency% <Daily 44.5 45.4 44.8
Dichotomous split Every day 55.5 54.6 55.2
0 = <daily/1 = daily
Intensity% (NRS) Mild pain (<4) 17.9 31.0 23.0
Dichotomous split Moderate pain (4–6) 58.5 50.9 55.6
0 = <5/1 = ≥5 Severe pain (7–10) 23.6 18.1 21.5
Time (duration)% <1 year 6.5 8.1 7.1
Dichotomous split 1-2 years 11.8 14.1 12.7
0 = <10 years 3–5 years 19.6 21.7 20.4
1 = >10 years 6–10 years 21.0 20.8 20.9
11–20 years 25.4 19.0 22.9
>20 years 15.8 16.2 15.9
Total pain sites% Single site 15.1 27.8 19.9
Dichotomous split 2-3 sites 30.8 41.2 34.8
1–3 sites = 0 4-5 sites 26.1 20.6 24.0
4–15 sites = 1 6–15 sites 27.9 10.4 21.3
FITT% 1 (4 low, 0 high) 6.4 11.7 8.5
Combined splits 2 (3 low, 1 high) 18.9 27.6 22.3
3 (2 low, 2 high) 30.5 32.6 31.3
4 (1 low, 3 high) 28.5 20.8 25.5
5 (0 low, 4 high) 15.7 7.2 12.3
those with large sample sizes which allows for a strong
population representation of the biological measures [30].
2.10. Statistical Analysis. Comparison of the risk composite
in individuals with chronic pain versus those individuals
without chronic pain was performed with a 𝑡-test. Multi-
variable comparisons were performed with analysis of vari-
ance (ANOVA), including sex, age group, education, health
behavior variables (smoking, alcohol, and exercise), and
mental health (HSCL ≥ 1.85) as cofactors. If nonsignificant
(𝑝 > 0.05), the covariate was excluded. A sex × chronic
pain interaction term was also tested in the model. Analyses
were repeated excluding participants reporting a diagnosis of
diabetes or attributing their pain symptoms to rheumatoid
arthritis or ankylosing spondylitis in order to evaluate the
relationship between chronic pain and the risk factor com-
posite eliminating the influence of conditions associated with
increased inflammatory and metabolic measures. Exclusion
of the identified conditions also controls for medications
associated with the treatment of those conditions, reducing
the influence of specific medications on the risk factor
composite [29].
The relationship between chronic pain severity and the
risk factor composite was investigated in individuals with
chronic pain with a stepwise multiple linear regression. In
Step 1, chronic pain severity, based on a combined FITT
measure, was entered along with covariates, sex, age group,
education, health behavior variables (smoking, alcohol, and
exercise), and mental health (HSCL ≥ 1.85), and then
excluded if nonsignificant (𝑝 > 0.05). A sex × chronic pain
severity interaction term was also included. Next, the health
behavior variables were entered in Step 2. Mental health was
entered in Step 3, that is, HSCL. If nonsignificant (𝑝 > 0.05),
a covariate was excluded from the final model.
A post hoc analysis was performed on the individual pain
dimensions to investigate their unique contribution. In Step
1 of the regression analysis pain duration, frequency, average
pain intensity, and total number of pain sites were entered,
along with sex, age, and education. Then health behaviors
were entered in Step 2. Mental health, as measured by the
HSCL, was excluded due to nonsignificance in prior models.
Resultswere considered significant if𝑝 < 0.05 for all analyses.
Lastly, a logistic regression was completed to determine the
relative association of each biomarker to chronic pain.
3. Results
Participant demographics and covariates in the model
are presented in Table 1. Additional information regarding
Tromsø 6 sample representation is provided by Eggen and
colleagues (2013). Distribution across the four pain dimen-
sions, frequency, intensity, time (duration), and total pain
sites and the chronic pain severity, based on combined FITT,
are presented in Table 2. The mean and standard deviation
for the individual components of the risk factor composite
are BMI (26.9 ± 4.3), CRP (2.5 ± 4.6mg/L), fibrinogen (3.5 ±
0.71 g/L), and triglycerides (1.5±0.97mmol/L). Following log
transformations and standardization, the mean and standard
deviation for the risk factor composite was 0 ± 1. A post hoc
analysis was completed to determine the relative association
of each biomarker to chronic pain; results are provided in
Table 3.
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Table 3: Odds ratio of risk factors measures and relationship to chronic pain.
Odds ratio estimates
Pr > ChiSq
Biomarker Point estimate∗ 95% confidence interval
Lower bound Upper bound
ZLN-CRP 1.051 1.001 1.103 0.044
ZLN-FBR 1.102 1.052 1.154 <0.0001
ZLN-TRI 1.017 0.978 1.058 0.396
Z-BMI 1.137 1.091 1.184 <0.0001
ZLN-CRP: C-reactive protein (CRP) log transformed z score.
ZLN-FBR: fibrinogen log transformed z score.
ZLN-TRI: triglycerides log transformed z score.
Z-BMI: body mass index (BMI) z score.
∗A value greater than 1.0 is associated with increased odds for chronic pain.
Table 4: Multivariable ANOVA of chronic pain and the risk factor composite.
Parameter 𝛽 Std. error 95% confidence interval Sig.
Lower bound Upper bound
Intercept −0.051 0.039 −0.126 0.025 0.191
Sex 0.179 0.022 0.137 0.222 <0.001
AGEGRP3 0.517 0.03 0.459 0.575 <0.001
AGEGRP2 0.505 0.024 0.458 0.552 <0.001
AGEGRP1 0.302 0.024 0.255 0.349 <0.001
HIGH EDU −0.175 0.018 −0.211 −0.139 <0.001
SMOKING2 0.192 0.025 0.143 0.241 <0.001
SMOKING1 0.117 0.02 0.078 0.155 <0.001
ALCOHOL3 −0.336 0.033 −0.401 −0.27 <0.001
ALCOHOL2 −0.215 0.031 −0.276 −0.154 <0.001
ALCOHOL1 −0.125 0.033 −0.189 −0.06 <0.001
EXERCISE3 −0.529 0.028 −0.583 −0.475 <0.001
EXERCISE2 −0.309 0.024 −0.355 −0.263 <0.001
EXERCISE1 −0.148 0.027 −0.2 −0.095 <0.001
CPAIN 0.206 0.024 0.159 0.254 <0.001
Sex ∗ CPAIN −0.087 0.037 −0.159 −0.015 0.017
Coding: dummy coding was completed for each of the following variables.
Age group (0 = 30–44; 1 = 45–59; 2 = 60–69; 3 = 70–87).
High education (0 = no; 1 = yes).
Smoking (0 = never; 1 = previously; 2 = currently).
Alcohol (0 = <2 units/mth; 1 = <3-4 units/mth; 2 = 5–16 units/mth; 3 = >16 units/mth).
Exercise (0 = <1x per week; 1 = 1x per week; 2 = 2-3x week; 3 = 4+x week).
3.1. Chronic Pain and the Risk Factor Composite. The risk
factor composite was significantly higher among individuals
with chronic pain (𝑀 = 0.13; SD = 0.98) compared to
those without chronic pain (𝑀 = −0.07; SD = 0.98), 𝑝 <
0.001. Multivariable ANOVA was performed, including sex,
age, smoking, exercise, alcohol, and HSCL as cofactors in the
analysis.The effects of chronic pain as well as the effects of all
cofactors were significant in the analysis (𝑝 < 0.001), with the
exception of HSCL which was not significant and excluded
(𝑝 = 0.386); results are presented in Table 4. In addition, a
significant sex by chronic pain interaction effect was found
(𝑝 = 0.017). To explore this interaction the analysis was
repeated for each sex independently. Chronic pain emerged
as a significant predictor of increased risk factor composite
for both sexes (𝑝 < 0.001), but the differences between
individuals with chronic pain and the comparison groupwere
greater among women than among men.
3.2. Comorbid Conditions. Additional analyses were com-
pleted excluding individuals reporting conditions that could
contribute to elevated inflammatory andmetabolicmeasures:
diabetes (𝑁 = 634), rheumatoid arthritis (𝑁 = 261), and
ankylosing spondylitis (𝑁 = 93). The overall sample size was
thereby reduced by 958 participants; however the relationship
between chronic pain and the risk factor composite, including
the covariates described above, was essentially not affected
(chronic pain, 𝛽 = 0.17; 𝑝 < 0.001).
3.3. Chronic Pain Severity. To explore whether there was a
dose-dependent relationship between chronic pain severity
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Table 5: Predictive model of chronic pain severity (FITT) and the risk factor composite.
Model 𝛽 Std. error 95% confidence interval Sig.
Lower bound Upper bound
(1) Constant −1.034 0.102 −1.234 −0.833 <0.001
Sex 0.319 0.101 0.121 0.517 0.002
Age 0.013 0.001 0.01 0.016 <0.001
High Edu −0.222 0.037 −0.294 −0.15 <0.001
FITT Total 0.126 0.02 0.087 0.165 <0.001
Sex X FITT −0.055 0.032 −0.117 0.007 0.081
(2) Constant −0.741 0.126 −0.987 −0.494 <0.001
Sex 0.287 0.099 0.092 0.481 0.004
Age 0.013 0.002 0.01 0.016 <0.001
High Edu −0.139 0.037 −0.211 −0.067 <0.001
FITT Total 0.113 0.02 0.074 0.151 <0.001
Sex X FITT −0.051 0.031 −0.111 0.01 0.099
Alcohol 1 −0.01 0.065 −0.139 0.118 0.875
Alcohol 2 −0.088 0.062 −0.21 0.034 0.156
Alcohol 3 −0.249 0.066 −0.378 −0.119 <0.001
Exercise 1 −0.147 0.052 −0.25 −0.044 0.005
Exercise 2 −0.286 0.046 −0.377 −0.195 <0.001
Exercise 3 −0.537 0.055 −0.644 −0.43 <0.001
Smoking 1 0.095 0.04 0.017 0.174 0.017
Smoking 2 0.168 0.047 0.075 0.26 <0.001
Coding: dummy coding was completed for each of the following variables.
Alcohol (0 = <2 units/mth; 1 = <3-4 units/mth; 2 = 5–16 units/mth; 3 = >16 units/mth).
Exercise (0 = <1x per week; 1 = 1x per week; 2 = 2-3x week; 3 = 4+x week).
Smoking (0 = never; 1 = previously; 2 = currently).
and the risk factor composite, stepwisemultiple linear regres-
sion analysis was performed on individuals who reported
chronic pain, using a combined measure of pain frequency,
intensity, time, and total number of pain sites (FITT) as
the main predictor. In Step 1, age, sex, and education were
included as covariates. Health behaviors (smoking, alcohol,
and exercise) were added in Step 2, and HSCL was added
in Step 3. As HSCL did not emerge as a significant pre-
dictor in the analysis, only results from Steps 1 and 2 are
presented in Table 5. Male sex, increasing age, and previous
and current smoking were all associated with a higher risk
factor composite, whereas higher education, exercise, and
alcohol consumption were found to be associated with a
lower risk factor composite. After entering these variables,
chronic pain severity (FITT) significantly predicted the risk
factor composite (𝛽 = 0.11; 𝑝 < 0.001, Step 2). Results
are presented in Figure 1, where no chronic pain group is
also included for comparison. A sex by FITT interaction was
not statistically significant. However, a sex by alcohol use
was significant, indicating that alcohol use was protective for
women only. As described above, additional analyses were
completed excluding individuals reporting conditions that
could contribute to elevated inflammatory and metabolic
measures; however, findings were minimally altered (FITT,
𝛽 = 0.09; 𝑝 < 0.001). The group difference in the mean risk
factor composite between FITT group 1 and FITT group 5
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Figure 1: Risk factor composite by chronic pain severity groups.
Adjusted for sex, age, education, alcohol use, exercise, and smoking.
Chronic pain severity groups: pain dimensions: frequency, intensity,
time, and total number of pain sites (FITT). 1 (low 4, high 0), 2 (low
3, high 1), 3 (low 2, high 2), 4 (low 1, high 3), 5 (low 0, high 4), and
∗
0 added to reflect no chronic pain.
deviation increase in the composite for those with severe
chronic pain.
3.4. Chronic Pain Dimensions. A post hoc analysis was
performed on all individuals reporting chronic pain to






















































































































Figure 2: Risk factor composite by pain dimensions. Unique effect of each pain dimension after controlling for sex, age, education, exercise,
alcohol consumption, smoking, and remaining pain dimensions.
determine the contributions of the chronic pain severity
measures: frequency, intensity, time (duration), and total
pain sites. In the regression analysis all four variables were
included along with all significant covariates from the main
analysis for chronic pain severity. This analysis revealed that
frequency (𝛽 = 0.57; 𝑝 = 0.001), intensity (𝛽 = 0.74; 𝑝 <
0.001), and total number of pain sites (𝛽 = 0.60; 𝑝 = 0.001)
were independently associatedwith the risk factor composite,
whereas time (𝛽 = −0.02; 𝑝 = 0.277) was not. Results are
presented in Figure 2.
4. Discussion
Our findings are the first to link chronic pain to a com-
posite of metabolic and immune measures associated with
cardiovascular disease and cancer. We found that individuals
with chronic pain have a higher risk factor composite than
individuals without chronic pain. Second, we also for the
first time demonstrated a “dose-response” pattern in the risk
factor composite based on five levels of chronic pain severity
even after controlling for relevant health behaviors and
mental health symptoms and excluding inflammation and
metabolic-related health conditions. Third, sex differences
were highlighted across analyses providing validation of
our findings. Lastly, health behaviors were associated with
differing levels of the risk factor composite in individuals with
chronic pain.
4.1. Chronic Pain. Our results provide evidence of a relation-
ship between chronic pain and physiological system func-
tioning, as previously proposed but not yet investigated [31–
33]. Although the relationship between chronic pain and an
array of individual biological measures has been investigated
[34–36], we are the first to show the predictive utility of a
composite measure reflecting immune and metabolic func-
tioning. As biological measures do not function in isolation
but rather contribute to dynamic, interactive systems, inves-
tigating a combination of measures reflecting overall system
functioning has demonstrated greater predictive utility than
evaluating individual measures [13–15, 29].
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4.2. Chronic Pain Severity. Investigations of chronic pain
are often limited to a dichotomous variable based on the
report of pain experienced within a three- to sixth-month
period which does not allow for differentiating from the
longer term experiences and consequences associated with
chronic pain. Differences in stress system responses have
been reported in individuals with episodic pain compared
to those with chronic pain following a low grade stressor
[24]. Additionally, in individuals with a minimum duration
of three years of episodic migraines, larger hippocampal
volume and greater functional connectivity of the region
were indicated in individuals with low frequency migraines
compared to individuals with high frequency migraines [25].
This study is the first to stratify individuals with chronic
pain by 5 levels of pain severity based on four common and
frequently asked pain-related questions regarding frequency,
intensity, time (duration), and total number of pain sites and
demonstrate an increasing biological risk factor composite
with increasing chronic pain severity.
In order to better reflect the biological burden of chronic
pain, a quantifiable measure of an individual’s pain expe-
rience is needed [10, 29]. For example, an individual with
persistent, high intensity, chronic pain in multiple body sites,
experienced for greater than eight years will likely have a
different biological burden compared to an individual who
has had an intermittent, low intensity, chronic pain for one
year in one body site. Essentially, by categorizing chronic pain
severity based on frequency, intensity, time (duration), and
total number of pain sites, our findings support the above
example: individual one’s pain experience is consistent with
pain severity FITT 5 and individual two with FITT 1. Of
note, a medium effect size was indicated in the difference of
the mean risk factor composite (0.4), from the least severe
chronic pain group (FITT 1) to the most severe chronic pain
group (FITT 5).
4.3. Pain Dimensions. Pain intensity, number of pain sites,
and pain-related disability are associated with increased
mortality [2, 5]. Our findings are specific to experiences of
chronic pain and indicate that the individual dimensions
of frequency, intensity, and total number of pain sites were
significant predictors of the risk factor composite, while pain
time (duration) was not. Results regarding duration may
have been influenced by the high proportion of long-term
chronicity of pain reported (median of 10 years). However,
chronicity (duration) is relevant in combination with the
severity of stress. As noted above, mild, intermittent, or
occasional pain for years would not be expected to result
in the same biological load when contrasted with persistent
(daily), moderate-to-severe pain for years. Hence, it appears
that the consideration of a combination of dimensions is
important in developing an index that will characterize pain
[26, 27, 37] as we demonstrate, to quantify the burden of
chronic pain.
4.4. Sex Differences. An interaction between sex and chronic
pain emerged such that differences in the risk factor compos-
ite between the no pain and chronic pain group were greater
for women than formen. Althoughwhen analysis was limited
to individuals with chronic pain, a sex and pain severity
interaction was not indicated, male sex was associated with a
higher risk factor composite. Sex differences in the prevalence
and severity of chronic pain have been widely reported [38].
Particularly, in general, women show greater frequency of
chronic pain and higher pain sensitivity. Less is known about
sex differences in immune and metabolic measures [39],
particularly in individuals with chronic pain. Consideration
of sex differences in future investigations of stress-related
biological measures and chronic pain is warranted.
4.5. Demographics and Health Behaviors. Increasing age and
higher educationwere associatedwith lower and higher levels
of the risk factor composite, respectively. Health behaviors
such as exercise and alcohol consumption were associated
with lower levels and smoking was associated with higher
levels of the risk factor composite. A previous study demon-
strated a relationship between previous lifestyle behaviors
associated with increased risk for cancer and cardiovascular
disease [body mass index, smoking, and diet (women)] and
chronic widespread pain [8]. Importantly, the current study
supports and extends the previously reported findings by
showing that, in individuals with chronic pain, adaptive
behaviors were associated with a lower risk factor composite
and a maladaptive behavior was associated with a higher risk
factor composite. Interestingly, retrospective behavioral self-
reports are often limited by reporting bias and poor memory
recall; however, each of the self-report indices demonstrated
surprisingly predictive patterns in relation to the risk factor
composite.
In regard to alcohol, health benefits have been reported
with low-to-moderate intake, particularly in older women
[40]. Greater than 16 units/month designation is within the
low risk and moderate consumption guidelines [41]. Addi-
tionally, findings in a population-based study indicate that in
individuals with chronic widespread pain the report of pain
disability decreases with increasing consumption of alcohol
until very high intake was reported, >35 units/week [42].
Most importantly, our findings suggest that (1) a biological
composite may be sensitive to behavioral interventions and
(2) adaptive and health promoting behaviors may reduce the
biological load on the system and slow pathophysiological
processes associated with chronic pain. These findings align
with brain imaging findings indicating that adaptive behav-
iors modify the changes in the brain associated with chronic
pain [37].
4.6. Theoretical and Mechanistic Considerations. There are a
number of possible mechanisms contributing to the chronic
pain and stress relationship. Dysregulated biological mea-
sures have been predictive of the onset of chronic pain and
indicated in chronic pain conditions [20, 35]. Both acute
pain and psychosocial stress can facilitate neuronal response
amplification contributing to central nervous system pain
sensitization, increasing the risk of chronic pain develop-
ment [43–46]. Once pain becomes chronic, individuals not
only experience the associated negative physiological arousal
but also frequently report increased psychosocial distress
[34, 47–50]. Additionally, health-related behaviors such as
Pain Research and Management 9
decreased exercise and physical activity, poor quality sleep,
social isolation, and maladaptive coping patterns such as
excessive alcohol consumption and smoking can further
increase the physiological burden on an individual’s system
[51, 52].
Inflammation represents one potential mechanism link-
ing chronic pain with increased morbidity and mortality
[53, 54]. Inflammation is implicated in acute and chronic pain
[36, 55, 56], is associated with psychosocial stress [57], and
can be influenced by health behaviors such as exercise and
sleep [58–60]. Similarly, dysregulated metabolic measures
have been associated with morbidity and mortality [29, 30,
61]. The pathophysiological changes associated with chronic
pain may contribute to dysregulated stress-related system
functioning, a recognized pattern termed allostatic load [62].
Inflammatory andmetabolicmeasures are included in studies
of stress system functioning and allostatic load formulations
[30]. Our findings of the dose response relationship between
the chronic pain severity and the risk factor composite align
with the allostatic load conceptualization.
4.7. Limitations and Future Directions. In order to fully
evaluate the relationship of chronic pain on physiological
functioning, additional biological measures need to be inves-
tigated including other inflammatory and metabolic indices
as well as cardiovascular, neuroendocrine, and genetic [10,
62, 63]. Second, given our large sample size, a 𝑧 score
composite was implemented in this study due to its sta-
tistical advantages; however, a clinically derived risk factor
composite has demonstrated utility and would be the next
step for clinical investigation [30]. Third, the cross-sectional
design limits causal inferences. Prospective studies will be
an important next step to evaluate the relationships between
changes in pain, comorbidities, health behaviors, and biologi-
calmeasures in order to better appreciate causal direction and
possible modulating relationships. Regardless of causation, a
composite measure of overall physiological functioning such
as allostatic load, sensitive to biological, psychological, behav-
ioral, and environmental changes, would be of great clinical
and research benefit. Fourth, findings based on lengthy
questionnaires can influence response rates. Importantly, the
overall nonresponse rate for questionnaire completion was
low with a 5–13% range indicated across the five primary
pain questions. In general, a review of responses suggests that
people tend to provide responses if they find the question
meaningful. Fifth, further investigation of medication usage
would be useful. We were not able to completely control
for NSAID use, which would result in lower inflammatory
levels, as such we are likely underestimating the relationship
between chronic pain and the risk factor composite. Sixth,
measuring chronic pain severity based on summing FITT
domains is a new conceptualization and will require further
testing, including comparing with other validated measures
such as the Graded Chronic Pain Scale, and completing a
formal validation study. Lastly, in the current investigation,
the values used as cut-offs for dichotomizing each pain
dimension were clinically quite high. The next step in this
developing line of investigation would be to further explore
optimal categorization of pain severity.
5. Conclusion
Individuals with chronic pain have a higher risk factor
composite than individuals without chronic pain, and the
risk factor composite increased in a dose-response fashion
based on chronic pain severity (FITT), even after controlling
for relevant cofactors and comorbidities. Our results build
on previous findings regarding chronic pain-related increases
in morbidity and mortality and support patterns identified
in brain imaging studies indicating changes in structure
and function are directly related to the frequency, intensity,
and duration of pain and modified by health behaviors
[37]. The identification and development of a biological
composite measure sensitive to varying levels of chronic pain
severity, adaptive/maladaptive behaviors, and pain treatment
interventions would have significant clinical and research
utility.
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